Spago Nanomedical AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	4.38	4.82	6.91	5.93	6.46	6.53
Revenue Growth (YoY)	-37.31%	-30.25%	16.56%	-8.19%	-1.10%	-9.85%
Gross Profit	4.38	4.82	6.91	5.93	6.46	6.53
Selling, General & Admin	18.39	19.65	25.71	23.67	24.84	23.53
Depreciation & Amortization Expenses	0.12	0.17	0.31	0.28	0.36	0.38
Research & Development	11.98	11.48	14.27	24.49	20.35	21.69
Other Operating Expenses	0.28	0.47	0.33	0.57	0.38	0.13
Total Operating Expenses	30.77	31.77	40.63	49	45.93	45.72
Operating Income	-26.39	-26.94	-33.71	-43.07	-39.47	-39.19
Interest Income	-	0.39	1.2	0.85	0.27	0.12
Total Non-Operating Income (Expense)	-	0.39	1.2	0.85	0.27	0.12
Pretax Income	-25.92	-26.55	-32.51	-42.22	-39.2	-39.07
Net Income	-25.92	-26.55	-32.51	-42.22	-39.2	-39.07
Net Income to Common	-25.92	-26.55	-32.51	-42.22	-39.2	-39.07
Shares Outstanding (Basic)	453	375	295	98	64	39
Shares Outstanding (Diluted)	453	375	349	105	64	40
Shares Change (YoY)	29.83%	7.25%	232.99%	63.55%	60.54%	44.10%
EPS (Basic)	-0.06	-0.07	-0.11	-0.43	-0.67	-1.10
EPS (Diluted)	-0.06	-0.07	-0.11	-0.43	-0.67	-1.10
Free Cash Flow	-25.13	-28.3	-34.67	-45.06	-38.32	-35.94
Free Cash Flow Per Share	-0.06	-0.08	-0.10	-0.43	-0.60	-0.90
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-601.85%	-558.77%	-487.68%	-726.24%	-610.91%	-600.00%
Profit Margin	-591.17%	-550.68%	-470.26%	-711.90%	-606.77%	-598.15%
FCF Margin	-573.15%	-586.83%	-501.49%	-759.77%	-593.20%	-550.25%
EBITDA	-26.39	-26.94	-33.71	-43.07	-39.47	-39.19
EBIT	-26.39	-26.94	-33.71	-43.07	-39.47	-39.19
EBIT Margin	-601.85%	-558.77%	-487.68%	-726.24%	-610.91%	-600.00%